France has initiated a recall of the rare disease drug Tavneos following reports of 20 deaths in Japan since 2022, which has led to the European Commission revoking its marketing authorization due to the risks associated with the drug outweighing its benefits.
Key Insights
Tavneos is specifically used to treat severe and rare autoimmune diseases that cause inflammation of the blood vessels. The drug's link to fatalities in Japan has raised significant concerns, resulting in the decision to pull it from the market to protect patient safety.
